Pattern of p63 expression in squamous cell carcinoma of the oral cavity
- 1 April 2004
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 444 (4) , 332-339
Abstract
P63 is a recently discovered gene harbouring different isoforms by alternate splicing. The two main isoforms, TAp63 and ΔNp63, have opposite functions, being responsible for cell-cycle arrest and cell proliferation, respectively. In addition, new isoforms have been described with the same sequence as TAp63 and ΔNp63, but lacking exon 4 (Δ4Tap63 and ΔNp73L). P63 as detected using immunohistochemistry is present in squamous cell carcinomas. To better define the role of p63 in squamous cell carcinomas of the oral cavity (OSCC), 39 patients were investigated using immunohistochemical analysis with a monoclonal antibody recognising all p63 isoforms and an anti-Ki67 antibody. Reverse-transcription polymerase chain reaction (PCR) and nested PCR were also performed using isoform-specific primers to evaluate the p63 mRNA expression pattern. Using immunohistochemistry, p63 was always present in OSCC, and its distribution was similar to that of Ki67. The percentage of positive cells increased from normal to neoplastic mucosa, but there was no relationship between the number of p63 positive cells and prognosis. P63 mRNA was found in all patients. The truncated isoforms Δ4TAp63 and ΔNp73L were more frequently expressed in patients presenting with metastases. ΔNp73L was found in 66.6% of tumours with lymph-node metastases, but in only 33.3% of those devoid of lymph-node metastases at presentation. An impaired expression of the p63 isoforms might favour cell proliferation and indirectly enhance the metastasising capacity of OSCC.Keywords
This publication has 18 references indexed in Scilit:
- p63 and TTF-1 Immunostaining: A Useful Marker Panel for Distinguishing Small Cell Carcinoma of Lung From Poorly Differentiated Squamous Cell Carcinoma of LungAmerican Journal of Clinical Pathology, 2003
- Loss of p63 Expression Is Associated with Tumor Progression in Bladder CancerThe American Journal of Pathology, 2002
- p63 In pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumorsHuman Pathology, 2002
- p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?The Journal of Pathology, 2002
- p63 and p73 are required for p53-dependent apoptosis in response to DNA damageNature, 2002
- Transcriptional dysregulation of the p73L / p63 / p51 / p40 / KET gene in human squamous cell carcinomas: expression of Δ Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51British Journal of Cancer, 2001
- p63 and p73: p53 mimics, menaces and moreNature Reviews Molecular Cell Biology, 2000
- Association of Directors of Anatomic and Surgical Pathology: recommendations for the reporting of specimens containing oral cavity and oropharynx neoplasms.2000
- p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative ActivitiesMolecular Cell, 1998
- A Second p53-Related Protein, p73L, with High Homology to p73Biochemical and Biophysical Research Communications, 1998